Solange Peters

Oct 9, 2024 | nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more

AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.

Jul 30, 2024 | onclive.com | Solange Peters

CommentaryVideoJuly 30, 2024Author(s):Solange Peters, MD, PhD, discusses biomarkers that may inform treatment decision-making prior to immunotherapy use in non–small cell lung cancer.

Nov 11, 2023 | nature.com | Solange Peters

AbstractPERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti–PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients with metastatic non-squamous NSCLC without known targetable genomic aberrations.

Aug 7, 2023 | onclive.com | Solange Peters

Solange Peters, MD, PhD, full professor, chair, Medical Oncology, Thoracic Malignancies Programme, Department of Oncology, University Hospital of Lausanne, discusses steps being taken to address the ongoing platinum chemotherapy shortage in the United States for patients with cancer.

Jul 27, 2023 | onclive.com | Solange Peters

Dr Peters on Understanding Mechanisms of Resistance to Immunotherapy in NSCLCSolange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer. Solange Peters, MD, PhD, full professor, chair, Medical Oncology, Thoracic Malignancies Programme, Department of Oncology, University Hospital of Lausanne, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.